Marina Kurian, MD
Surgery · New York, NYNPI 1598824971
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.1%), consulting fees and gifts — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Novo Nordisk at 39.7% of the total. Reporting peaked in 2024 at $103,785 and has fallen 55.1% since, to $46,577 in 2025. Among surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 457 payments — averaging $717.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$130K
- Medtronic$62K
- W. L. Gore & Associates, Inc.$35K
- AbbVie$24K
- Covidien LP$21K
- Vivus LLC$18K
- plus $39K from 25 others
What the payments were for
- Consulting fees$90,03627%
- Speaking & faculty fees$177,58154%
- Travel & lodging$15,1035%
- Food & beverage$21,3367%
- Education$1620%
- Gifts$23,2567%
- Entertainment$5650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 108 | $130,192 |
| Medtronic | 135 | $61,749 |
| W. L. Gore & Associates, Inc. | 40 | $34,862 |
| AbbVie | 2 | $23,791 |
| Covidien LP | 30 | $20,558 |
| Vivus LLC | 19 | $17,870 |
| Stryker | 11 | $17,033 |
| Johnson & Johnson | 9 | $10,349 |
| Medical Device Business Services, Inc. | 10 | $3,985 |
| Heron Therapeutics, Inc. | 3 | $2,326 |
| Apollo Endosurgery US Inc | 4 | $1,191 |
| Reshape Lifesciences Inc. | 11 | $1,138 |
| Intuitive Surgical | 10 | $796 |
| Intra-sana Laboratories | 8 | $419 |
| Lilly USA, LLC | 17 | $298 |
| Currax Pharmaceuticals LLC | 15 | $224 |
| Merz North America, Inc. | 3 | $151 |
| Davol Inc. | 1 | $139 |
| Levita Magnetics International Corp | 2 | $133 |
| Integra Lifesciences Corporation | 1 | $129 |
| Aesculap, Inc. | 1 | $128 |
| Pfizer | 1 | $125 |
| TELA Bio, Inc. | 1 | $121 |
| Teleflex LLC | 3 | $66 |
| Endo Pharmaceuticals Inc. | 3 | $57 |
| Ambu Inc. | 1 | $56 |
| Olympus America Inc. | 1 | $45 |
| Eisai Inc. | 3 | $43 |
| Nalpropion Pharmaceuticals LLC | 2 | $32 |
| Shire North American Group Inc | 1 | $20 |
| Innocoll Pharmaceuticals Limited | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$128,829
- GORE BIO-A Tissue Reinforcement$28,797
- GORE ENFORM Preperitoneal Biomaterial$27,895
- GORE SEAMGUARD Bioabsorbable Staple Line Reinforce$19,604
- QSYMIA$17,683
- GORE SYNECOR Biomaterial$11,514
- ECHELON ENDOPATH$10,141
- Echelon Flex$10,141
- 1688$9,657
- SPY-PHI SYSTEM$6,733
- Signia$5,764
- AIM$5,500
- Sonicision$4,492
- 1788$4,000
- Echelon Circular$2,778
- Endopath Xcel$2,778
- Harmonic$2,778
- Zynrelef$2,250
- OverStitch Endoscopic Suturing System$1,018
- LigaSure$985
How this compares
$328,039 in reported general payments places this provider in the 95th percentile of 1,596 surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 55 | $73,591 |
| MounjaroTirzepatide | 25 | $29,235 |
| TrulicityDulaglutide | 18 | $18,295 |
| LinzessLinaclotide | 13 | $8,736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $130,192 | $73,59155 claims |
| Lilly USA, LLCMounjaro, Trulicity | $298 | $47,53043 claims |
| AbbVieLinzess | $23,791 | $8,73613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 surgery providers in New York.
Other surgery in New York
- Cheguevara AfanehNew York$1.4M
- Flavio Malcher Martins de OliveiraNew York$695K
- Yuri NovitskyNew York$548K
- Rasa ZarnegarNew York$478K
- Tanuja DamaniNew York$459K
- Rache SimmonsNew York$371K
- Megan JenkinsNew York$290K
- Brian JacobNew York$225K
- Robin BlackstoneNew York$174K
- Mitchell RoslinNew York$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.